Advanced searches left 3/3
Search only database of 8 mil and more summaries

Ats Mayer Albumin

Summarized by PlexPage
Last Updated: 02 July 2021

* If you want to update the article please login/register

General | Latest Info

Acute respiratory distress syndrome constitute a significant disease burden with regard to both morbidity and mortality. Current therapies are mostly supportive and do not address underlying pathophysiologic mechanisms. Removal of protein-rich alveolar edemaa clinical hallmark of acute respiratory distress syndromeis critical for survival. Here, we describe a transforming growth factor-trigger mechanism, in which megalin, primary mediator of alveolar protein transport, is negatively regulated by glycogen synthase kinase 3, with protein phosphatase 1 and nuclear inhibitor of protein phosphatase 1 being involved in signaling cascade. Inhibition of GSK3 rescue transepithelial protein clearance in primary alveolar epithelial cells after TGF-treatment. Moreover, in the bleomycin-base model of acute Lung injury, megalin + /-animals show marked increase in intra-alveolar protein and more severe Lung injury compared with wild-type littermates. In contrast, wild-type mice treated with clinically relevant GSK3 inhibitors, tideglusib and valproate, exhibited significantly decreased alveolar protein concentrations, which was associated with improved lung function and histopathology. Together, we discover that TGF-GSK3-megalin axis is centrally involved in disturbances of alveolar protein clearance in acute Lung injury and provide preclinical evidence for therapeutic efficacy of GSK3 inhibition. With the incidence of approximately 200 000 patients annually in the United States, acute respiratory distress syndrome constitute a significant disease burden with regard to both morbidity and mortality. Treatment strategies for ARDS are supportive, and do not address underlying pathophysiologic mechanisms. Accumulation of protein-rich alveolar edema, secondary to endothelial and epithelial injury, causes severe impairment of gas exchange and, therefore, hypoxia, which leads to further disruption of alveolar epithelial function and fluid balance. Elevated levels of precipitate protein can be found in the alveolar space of patients with ARDS. Importantly, nonsurvivors of ARDS exhibit threefold-higher levels of precipitate protein in edema fluid than do survivors of disease. Therefore, removal of excess protein from alveolar space is essential for resolution of ARDS. We have previously demonstrated that, in rabbit lungs as well as in primary alveolar epithelial cell monolayers, albumin is actively transported across the alveolar epithelial barrier by high-capacity endocytic process mediated by megalin, 600-kD glycoprotein member of the low-density lipoprotein receptor superfamily. Transforming growth factor-has been described as a key mediator, not only in late fibroproliferative phase of ARDS, but also in early injury. In various murine models of acute Lung injury, TGF-impairs epithelial permeability and transepithelial sodium transport capacity, thus promoting pulmonary edema. Similar findings have been described in human patients with ARDS. Glycogen synthase kinase 3 is a ubiquitously express, highly conserve serine / threonine protein kinase signaling molecule found in all eukaryotes. GSK3 participates in a wide spectrum of cellular processes, including glycogen metabolism, transcription, translation, cytoskeleton regulation, intracellular vesicular transport, cell cycle progression, and apoptosis. In cell, GSK3 is constitutively phosphorylated, and thereby inactivate. To be activate, GSK3 must be dephosphorylated. Mammals express two GSK3 isoforms, GSK3 and GSK3, that are 98 % structurally identical.

* Please keep in mind that all text is machine-generated, we do not bear any responsibility, and you should always get advice from professionals before taking any actions.

* Please keep in mind that all text is machine-generated, we do not bear any responsibility, and you should always get advice from professionals before taking any actions

Introduction

Critical Care clinicians have the opportunity to choose among several intravenous solutions for fluid replacement. These fall into two broad categories: crystalloids and colloids. The fundamental physiologic difference between these two is that colloid solutions generate protein or colloid osmotic pressure. Appropriate indications for use of either crystalloid or colloid solution have been debated for decades and were highlighted by publication of systematic reviews that conflict in their estimates of benefit or detriment attributable to colloids. On basis of inherent limitations of systematic reviews and meta-analyses, considerable criticism was directed at both the methods and conclusions of these studies. Colloids have theoretical advantages according to Starling's Law, with greater volume expansion per unit infuse and maintenance of COP. Colloids can be distinguished as being synthetic or nonsynthetic. Each type is associated with several real or hypothetical risks. For example, synthetic colloids have been associated with coagulopathy, anaphylactoid reactions, and end-organ damage, whereas albumin is derived from pool plasma collection, and thus carries potential risk of infection. Low serum albumin levels have been associated with poor survival in critically ill patients, and hypoproteinemia is a licensed indication for albumin therapy. Intravenous solutions consume a substantial portion of pharmacy budgets, with crystalloids being less expensive than colloids, and albumins most costly. Critical Care physicians are one of the groups of physicians that most commonly prescribe colloids. In light of the high use of colloids in Critical Care, their potential for adverse effects, their relatively high cost, and lack of Consensus regarding their use, mission of this Working Group was to review evidence supporting use of colloids in specific clinical conditions, and to provide recommendations for future research opportunities, particularly when current knowledge is insufficient to make strong evidence-base recommendations for clinical use. This Working Group was formed under auspices of Critical Care Assembly of American Thoracic Society. The goal was to critically review literature relating to natural and synthetic colloids with particular focus on patients in Medical, surgical, and cardiovascular Intensive Care units, excluding thermally injured and pediatric patients. We identify articles by performing systematic search of MEDLINE and Cochrane Library. We begin this review by searching for relevant English language articles, using uniformly adopted keyword base for consistency: albumins, colloids, dextrans, gelatin, hetastarch, isotonic solutions, plasma substitute. Retrieve articles were categorized according to subcommittees described below, and additional references were identified using topic-specific keywords. This search includes all references produced from 1996 to 2002, and by hand searching bibliographies of retrieved articles and additionally cull from personal files of Working Group members. To ensure complete data review, request for additional unpublished data was made to producers of natural and synthetic colloids. NO additional data was discover. Specific evaluation of existing systematic reviews and analysis was undertake.

* Please keep in mind that all text is machine-generated, we do not bear any responsibility, and you should always get advice from professionals before taking any actions.

* Please keep in mind that all text is machine-generated, we do not bear any responsibility, and you should always get advice from professionals before taking any actions

Biophysical Characterization

Protein identity was confirmed by MALDI-TOF mass spectrometry. Analytical ultracentrifugation experiments were performed on 30 M protein samples in PBS supplemented with 1 M M trisphosphine using Beckman Optima XL-I analytical ultracentrifuge. The AUC run was conducted at 4 C and 15 000 rpm, using absorbance at 280 nM for monitoring equilibrium. Circular dichroism spectra were collected in PBS supplement with 1 M M DTT and at protein concentration of 25 M. Chirascan spectropolarimeter with 0. 1 cm path length was used for the CD. Thermal stability experiments were performed using a 1 C / min temperature ramp between 10 C and 90 C and monitored by CD at 222 nM. Static light scattering experiments were performed on samples of 2-4 mg / ml concentration in PBS, using S-200 analytical size exclusion chromatography column connected in-line to miniDAWN TREOS light scattering and Optilab T-rEX refractive index detectors. Fluorescence anisotropy experiments were performed using PHERAstar FS microplate reader. Fluorescein-label ATS-FL at 0. 5 M concentration in NMR buffer was excite at 485 nM and polarization was recode at 520 nM.

* Please keep in mind that all text is machine-generated, we do not bear any responsibility, and you should always get advice from professionals before taking any actions.

* Please keep in mind that all text is machine-generated, we do not bear any responsibility, and you should always get advice from professionals before taking any actions

NMR Spectroscopy and Structure Determination

Rosmarinic acid consists of two phenolic acids, caffeic and Salvianic acid. Enzymatic formation of caffeic and Salvianic acid arise from 4-coumaroyl-CoA and 4-hydroxyphenyllactic acid, respectively, which are, also, two basic biosynthetic precursors of rosmarinic acid 43 44. Thus, plant biosynthetic machineries have evolved to combine simpler structural components to generate molecules with higher structural complexity. Whether this structural complexity leads to greater biological potency depends on the specific target. For example, binding of rosmarinic acid to BSA reduces its inhibitory effect against acetylcholinesterase and at the same time enhances its antioxidant capacity 45. Rosmarinic and caffeic acid have been previously studied on their interaction with serum albumin 9 46-48 while there is only one study for interaction of Salvianic acid with BSA 49. Fluorescence spectroscopy is the dominant technique used to elucidate these interactions. However, here for the first time, binding of rosmarinic acid to BSA is investigated in relation to binding of its two submoieties to the same protein in a more detailed way by utilising sophisticated techniques. In addition, we describe synthetic process with improved yield for Salvianic acid. Salvianic acid, natural product originally isolated from plant Salvia miltiorrhiza, is a bioactive compound presenting antioxidant and anti-inflammatory properties 50 51. In vivo, it has illustrated cardioprotective effects in rats with myocardial infraction 52 and myocardial ischaemia injury 53, and mice with increased levels of homocysteine 51 while it, also exhibits protective effects in mice with acute liver injury 54. Above evidence indicates the therapeutic potential of Salvianic acid and further investigation in preclinical and clinical stages could reveal its benefits in human health. However, currently large clinical trials or large scale studies are limited due to restricted availability of Salvianic acid. This is a common problem for natural products 55, as only small amounts can be isolate. In such cases, total organic synthesis can assist. Many synthetic procedures for Salvianic acid have been reported, including its synthesis from commercially available compounds such as 3 4 dihydroxy benzaldehyde 15 16 19 and its hydrolysis from rosmarinic acid and other natural products with both chemical and enzymatical reactions 17 20 56-58. Although, these methods suffer from low yields, many reaction steps that diminish yield and also produce large amount of waste. To overcome these drawbacks, we apply methanolysis of rosmarinic acid to its precursors with mild conditions and no waste production. To achieve that, different conditions were tested ending up to an optimum 4 H reaction utilising 1 M NaOH, while unreacted materials are bioactive compounds caffeic and rosmarinic acids which can be further hydrolyse. We, also, observe that longer reaction times lead to larger amounts of caffeic acid while the starting material was completely consumed and almost no Salvianic acid was recover. The main reason for this is subsequent elimination of produce Salvianic acid due to alkaline conditions as reaction time progress. Interaction with BSA of all three phenolic acids was first confirmed through fluorescence spectroscopy.

* Please keep in mind that all text is machine-generated, we do not bear any responsibility, and you should always get advice from professionals before taking any actions.

* Please keep in mind that all text is machine-generated, we do not bear any responsibility, and you should always get advice from professionals before taking any actions

Uses for Albumin Human

For decades, Human Albumin has been administered to patients to provide adequate oncotic pressure and intravascular volume. 1 in 1998, However, report from Cochrane Injuries Group Albumin Reviewers indicated that Administration of Albumin may be potentially harmful in critically ill patients, as compared with Administration of crystalloid solutions. 2 Subsequent meta-analyses report contradictory findings. 3 4 To clarify this issue, large, double-blind, randomized trial 5 was conduct, in which 4 % of Albumin solution was compared with normal Saline as Fluid replacement in critically ill Patients, With Results indicating that Albumin Administration was SAFE. A Predefined subgroup analysis shows that patients with severe sepsis receiving Albumin were at a lower, although not significantly lower, risk of death than those receiving normal Saline. In addition, Subsequent Study points out the potential benefit of maintaining Serum Albumin at level of more than 30 g per liter in critically ill patients. 6 there is a convincing rationale for potential advantages of Albumin Administration during severe sepsis. 7 Albumin is the main protein responsible for plasma colloid osmotic pressure 8; It acts as carrier for several endogenous and exogenous compounds, 9 with antioxidant and antiinflammatory properties, and as scavenger of reactive oxygen 10 11 and nitrogen 12 species and operates as a buffer molecule for acid-base equilibrium. 13 We therefore conducted a randomize, control trial to investigate the effects of administration of Albumin and crystalloids, as compared with crystalloids alone, targeting Serum Albumin level of 30 g per liter or more in population of patients with severe sepsis. The main results of this large-scale trial provide evidence regarding both the efficacy and safety of use of Human Albumin During severe sepsis interventional strategy that has long been debate. 21 22 addition of Albumin To crystalloids During first 28 days of treatmeNt To maintain Serum Albumin level of 30 g per liter or more is SAFE but does not provide survival advantage over crystalloids alone, over follow-up period of 90 days. Similar findings were observed in subgroup stratify according to interval between time patient met clinical criteria for severe sepsis and treatmeNt application. Findings in our trial may appear to contradict those of predefined subgroup analysis from SAFE Study, 5 which suggest survival advantage with Albumin-base strategy during severe sepsis. The plausibility of this hypothesis was supported by significant hemodynamic advantages observed 23 and by further Investigations showing that correction of hypoalbuminemia reduces severity of Organ dysfunction. 4 6 Similar beneficial effects were also suggested by a large meta-analysis, which concluded that use of Albumin-containing solutions could be associated with lower mortality than that seen with other Fluid regimens. 24 our Results confirm that Administration of Albumin produces small but significant hemodynamic advantages. A significantly greater proportion of patients in the Albumin Group than in the crystalloid Group reach target mean arterial pressure within 6 hours after randomization.

* Please keep in mind that all text is machine-generated, we do not bear any responsibility, and you should always get advice from professionals before taking any actions.

* Please keep in mind that all text is machine-generated, we do not bear any responsibility, and you should always get advice from professionals before taking any actions

Albumin Human Dosage and Administration

The Clinical relevance of PPB displacement, resulting in clinically relevant DDI has been an area of much discussion and debate. 3 10 61 110-117 There are several examples in literature where PPB displacement was originally proposed to cause clinical risk, especially those with warfarin, tolbutamide, and phenytoin, But recent evaluation of these DDIs reveal that inhibition of metabolism of victim Drugs by corresponding perpetrator Drugs, rather than Protein Binding displacement, To be culprit in these cases. Applying basic PK principles, experts' opinion suggest that proteinbinding displacement can result in the need to adjust dose of new chemical entity in cases only when SS Unbound concentration of NCE changes. Theoretically, this may happen in three scenarios with high extraction drugs only, that have NTI when administered IV and have very short PK / PD equilibration time. In most cases, displacer drug is added slowly and this allows unbound concentration of displaced drug to redistribute after transient increase and return to its predisplaced state, thus affecting PD minimally. In contrast, in the case of acute therapies, when bolus dose of displacer is administered via IV route, rapidly increased Free Drug concentration has a chance to reach receptors or tissue compartments at high concentration, before redistribution. Sulfonamide ADMINISTRATION To neonates via IV route, exemplify this scenariothe antibacterial sulfonamides quickly cross placental barrier and competes with bilirubin for Binding To serum Albumin, causing rapid increase of bilirubin in neonates. Free bilirubin causes hyperbilirubinimia, jaundice and enters CSF at high concentration to cause kernictus 114. Another scenario where PPB may have clinical relevance is in the case of drugs that are administer PO but with nonhepatic route of Cl 110. Propafenone is an interesting case where, although the drug is administered PO and undergoes hepatic extraction, due to its high PPB, high Cl, and short PK / PD equilibration time, and NTI, PPB displacement can be clinically significant. Nonetheless, when developing NCEs that possess NTI, such as those used in critical treatments such as antiarrhythmia, anesthetic / pain medication, anticoagulants, anticonvulsants, antidepressants, it is advisable to evaluate possible Protein Binding displacements that could lead to DDI. Rate limiting steps involved in Cl of Drug, major route of Cl, and the need to differentiate transient effect on PPB displacement versus final value of PPB in SS situation is very important. It is also important to recognize that although SS Unbound concentration of Drug may remain unchanged, transient fluctuations in Unbound Drug concentration may warrant changes in loading dose or dosing interval, If fluctuation of Unbound Drug concentration is excessive. Because AAG is a low capacity Protein, it is possible to saturate its binding sites with drugs at normally encounter therapeutic concentration range. AAG levels have been reported to significantly increase in case of disease States 95 118 and the implications of an increase in Unbound concentrations of drugs that bind strongly to AAG, such as lidocaine, quinidine, and alfentanil, have received careful consideration.

* Please keep in mind that all text is machine-generated, we do not bear any responsibility, and you should always get advice from professionals before taking any actions.

* Please keep in mind that all text is machine-generated, we do not bear any responsibility, and you should always get advice from professionals before taking any actions

Cautions for Albumin Human

Dr. Joseph Ferro, Assistant Medical Director Bristol-Myers Squibb Company One Squibb Drive Post Office Box 191 New Brunswick, New Jersey 08903-0191 This is in response to your letter of November 10 1992, in which you requested interpretation regarding Occupational Safety and Health ADMINISTRATION regulation 29 CFR 1910. 1030, Occupational Exposure To Bloodborne Pathogens. Specifically, you request that Albumin Human USP be excluded from coverage under standard. You state that this product is prepared via cold ethanol fractionation process, heat treated to kill Bloodborne Pathogens, tested as per FDA approved procedures and is considered safe for intravenous use. You submit a package of literature and data intend to support your contention that this product poses no risk to employees who handle it in our manufacturing facility. You also include a supporting letter from New Jersey Blood Services. OSHA has reviewed the material you submit and has decided that Albumin Human USP cannot be excluded from the standard's definition of Blood on the basis that it is not infectious material AND, therefore, that employees who handle it are covered under the scope of regulation. During the public comment period that followed publication of OSHA's proposed standard, agency received comments from at least two parties stating that some human blood products such as sterile human Albumin do not present risk and recommending that the definition of Blood be amended to exclude products that have been treated To render Bloodborne Pathogens noninfectious. In issuing the final standard, OSHA was concerned with lack of information in public record dealing with such treatment and leave stand definition. Allowance was made for exception to labeling requirement for these products. Sterility is a process that is determined by lot and / or batch validation. Sterility validation data is scrutinized under appropriate statistical sampling methodology which ensure acceptability of lot being characterized as sterile. It is our understanding that all methods of validation, statistical validation methodologies, and data review fall under the regulatory mandate of Food and Drug ADMINISTRATION and its regional laboratories. FDA compliance inspections may include validation of sterility for representative sample of a specific product as well as records review of overall sterilization procedures. This, however, does not ensure that a specific lot is sterile and / or pyrogen-free. At the same time, OSHA has decided that failure to provide employees handling only this product with certain protections of Bloodborne Pathogens standard will be considered technical de minimis violation bearing no penalties providing that FDA certificate of analysis validating sterility and issue within preceding two years is available For Product in question. Such certification was not included in your package and letter from New Jersey Blood Services would not suffice for this purpose.


Description and Brand Names

Albumin injection is used to treat low blood volume. It is also used to treat low albumin levels in the blood caused by: not enough albumin produce by body, excessive breakdown of albumin, loss of albumin from body, or redistribution of albumin from body. Albumin injection is also used to treat hypoalbuminemia in patients with severe injuries, infections, or pancreatitis that cannot be quickly reversed and when nutritional supplements have been given but do not work well. It is also used together with crystalloid treatment to correct lower osmotic pressure in the blood and to replace protein loss caused by severe burns after the first 24 hours. Albumin injection is used as priming fluid during cardiopulmonary bypass surgery. Flexbumin 25 % is used when hypovolemia is long-standing and hypoalbuminemia exists along with enough hydration, or fluid swelling. It is also used together with other medicines to treat fluid swelling in lungs and hypoproteinemia in patients with adult respiratory distress syndrome. Flexbumin 25 % is also used to treat swelling in patients with severe nephrosis who are receiving steroids or water pill. It is also used to treat hemolytic disease of newborn babies. This medicine is to be given only by or under direct supervision of your doctor. Solution copyright 2020 IBM Watson Health. All rights reserve. Information is for the end user's use only and may not be sell, redistributed or otherwise used for commercial purposes.


5.5.1 Acute Volume Replacement

Human albumin is considered to be indicate for volume replacement in cardiac surgery. In particular, risk of excessive bleeding when administering older synthetic colloids is seen as rationale for application of human albumin since no relevant substance-specific alterations regarding coagulation have been reported for human albumins use. The majority of studies reporting benefits when using human albumin solutions in the context of cardiac surgery originate from the USA. However, no modern synthetic colloids with few adverse reactions are available there. Therefore, results of retrospective analysis of data that report lower incidence of mortality in cardiac surgery patients when using human albumin must be interpreted with caution because no specifics were given for volume substitutes used as alternative. In a meta-analysis published in 2001, Wilkes and co-workers compared risk of postoperative bleeding following administration of older HES preparations with either high or medium molecular weight and high degree of substitution in the context of cardiac surgery. Human albumin and HES were administered as volume replacement prior to and after cardiopulmonary bypass, respectively, and also as constituents of priming fluid of extracorporeal circuit. In nine trials involving 354 patients, the effects of first-generation starch and albumin were compare. Postoperative blood loss was significantly lower in patients exposed to albumin than in those exposed to HES. If in contrast, more modern synthetic colloid solution was administer, there was no longer a statistically significant difference in comparison to albumin under conditions of systematic meta-analysis.

* Please keep in mind that all text is machine-generated, we do not bear any responsibility, and you should always get advice from professionals before taking any actions.

* Please keep in mind that all text is machine-generated, we do not bear any responsibility, and you should always get advice from professionals before taking any actions

Actions

Albumin is an important factor in regulation of plasma volume and tissue fluid balance through its contribution to colloid oncotic pressure of plasma. 204 205 206 207 208 210 211 212 213 214 215 254 255 256 Albumin is a highly soluble globular protein with relatively low molecular weight and exerts 70-80 % of colloid oncotic pressure of normal plasma. 206 208 210 211 212 215 226 254 255 256 IV administration of concentrated Albumin human solution causes shift of fluid from interstitial spaces into circulation and a slight increase in concentration of plasma proteins. 204 205 206 207 208 214 215 254 255 256 in US, Albumin humans is commercially available as 5 20, or 25 % solutions; 204 205 206 207 208 210 211 212 213 214 215 254 255 256 other concentrations are available in other countries. 250 Albumin human 5 % solution is iso-oncotic with normal human plasma and will expand circulating blood volume by an amount approximately equal to the volume infuse. 210 211 212 213 When administering IV in well-hydrate patients, each volume of albumin human 20 or 25 % solution draw about 2. 5 or 3. 5 volumes, respectively, of additional fluid into circulation within 15 minutes, reducing hemoconcentration and blood viscosity. 204 205 206 207 208 215 In patients with reduced circulating blood volumes, hemodilution persists for many hours. 204 205 206 207 208 210 212 215 in patients with normal blood volume, excess fluid and protein are lost from circulation within a few hours. 204 205 206 207 208 210 212 215 When used for treatment of hypovolemia, most effective in well-hydrate patients. 208 215 254 255 is 256 is not considered and should not be used as an IV nutrition source. 21 204 206 Binds and functions as carrier of intermediate metabolites, trace metals, some drugs, dyes, fatty acids, hormones, and enzymes, thus affecting transport, inactivation, and / or exchange of tissue products. 20 21 204 205 208 213 226 230 231

* Please keep in mind that all text is machine-generated, we do not bear any responsibility, and you should always get advice from professionals before taking any actions.

* Please keep in mind that all text is machine-generated, we do not bear any responsibility, and you should always get advice from professionals before taking any actions

Advice to Patients

Advise patient and / or patient's caregiver of benefits and risks of albumin human. 204 205 206 207 208 210 211 212 213 214 215 254 255 256 Advise patient and / or patient's caregiver that albumin human is prepared from pool human plasma. 204 205 206 207 208 210 211 212 213 214 215 254 255 256 improved donor screening and viral-inactivating procedures used in manufacture of Plasma-derive Preparations have reduce, but not entirely eliminate, risk of pathogen transmission. 204 205 206 207 208 210 211 212 213 214 215 254 255 256 Importance of reporting any infection believed to have been transmitted by albumin human. 204 205 207 208 210 211 213 214 215 254 255 256 Importance of discontinuing immediately if allergic symptoms or other severe adverse reactions occur. 254 255 256 Importance of informing clinicians of existing or contemplate concomitant therapy, including prescription and OTC drugs, as well as any concomitant illnesses. 204 205 206 207 208 210 211 212 213 214 215 Importance of women informing clinicians if they are or plan to become pregnant or plan to breast-feed. 204 205 206 207 208 210 211 212 213 214 215 254 255 256 Importance of informing patients of other important precautionary information. 204 205 206 207 208 210 211 212 213 214 215 254 255 256

* Please keep in mind that all text is machine-generated, we do not bear any responsibility, and you should always get advice from professionals before taking any actions.

* Please keep in mind that all text is machine-generated, we do not bear any responsibility, and you should always get advice from professionals before taking any actions

Sources

* Please keep in mind that all text is machine-generated, we do not bear any responsibility, and you should always get advice from professionals before taking any actions.

* Please keep in mind that all text is machine-generated, we do not bear any responsibility, and you should always get advice from professionals before taking any actions

logo

Plex.page is an Online Knowledge, where all the summaries are written by a machine. We aim to collect all the knowledge the World Wide Web has to offer.

Partners:
Nvidia inception logo

© All rights reserved
2021 made by Algoritmi Vision Inc.

If you believe that any of the summaries on our website lead to misinformation, don't hesitate to contact us. We will immediately review it and remove the summaries if necessary.

If your domain is listed as one of the sources on any summary, you can consider participating in the "Online Knowledge" program, if you want to proceed, please follow these instructions to apply.
However, if you still want us to remove all links leading to your domain from Plex.page and never use your website as a source, please follow these instructions.